MG
TSVT

Michael Gelband’s 2seventy bio TSVT Stock Holding History

Michael Gelband’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$770K – 2107
2024
Q2 		$770K Buy
+200,000
New +$902K 0.01% 1103

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Michael Gelband's TSVT Position: Q3 2024 in Review

Michael Gelband sold out of 2seventy bio (TSVT) in Q3 2024, closing a stake of 25,161 shares — an estimated $97K sold.

Michael Gelband first reported a position in TSVT in Q4 2021 and held it in 9 quarters. The position peaked at $14.7M in Q2 2023. 115 funds tracked by Wall St. Rank hold TSVT as of Q3 2024.

  • Michael Gelband reported no remaining 2seventy bio position as of Q3 2024 after selling out during the quarter.
  • Michael Gelband sold 25,161 2seventy bio shares in Q3 2024, an estimated $97K.
  • Michael Gelband first reported a position in 2seventy bio in Q4 2021 and held it in 9 quarters.
  • Michael Gelband's 2seventy bio position peaked at $14.7M in Q2 2023.
  • 115 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.